NCT00709527View on ClinicalTrials.gov

ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 16, 2008

Primary Completion Date

December 30, 2009

Study Completion Date

December 30, 2009

Conditions
Neovascular Age-Related Macular Degeneration
Interventions
DRUG

Avacincaptad Pegol

intravitreal injection

Trial Locations (1)

10119

Ophthotech Corp, New York

Sponsors
All Listed Sponsors
lead

Ophthotech Corporation

INDUSTRY

NCT00709527 - ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter